Compare FPH & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FPH | STRO |
|---|---|---|
| Founded | 2009 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 366.9M | 332.8M |
| IPO Year | 2013 | 2018 |
| Metric | FPH | STRO |
|---|---|---|
| Price | $4.58 | $15.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $47.23 |
| AVG Volume (30 Days) | 143.8K | ★ 284.8K |
| Earning Date | 10-28-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $110,020,000.00 | $38,419,000.00 |
| Revenue This Year | $1,459.63 | N/A |
| Revenue Next Year | $5.38 | N/A |
| P/E Ratio | $11.40 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.55 | $0.72 |
| 52 Week High | $6.47 | $43.85 |
| Indicator | FPH | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 30.90 | 31.62 |
| Support Level | $4.57 | $14.81 |
| Resistance Level | $5.18 | $17.33 |
| Average True Range (ATR) | 0.11 | 0.92 |
| MACD | -0.02 | 0.21 |
| Stochastic Oscillator | 15.40 | 44.34 |
Five Point Holdings LLC is an owner and developer of mixed-use, master-planned communities in California. It is engaged in developing new communities that, in addition to homesites, include commercial, retail, educational, and recreational elements, as well as civic areas, parks, and open spaces. Its four reportable segments are Valencia, San Francisco, Great Park, and Hearthstone. It derives the majority of revenue from the Great Park segment, which includes Great Park Neighborhoods being developed adjacent to and around the Orange County Great Park, a metropolitan park under construction in Orange County, California.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.